Compare · CERS vs RDDT
CERS vs RDDT
Side-by-side comparison of Cerus Corporation (CERS) and Reddit Inc. (RDDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and RDDT operate in EDP Services (Technology), so they compete in similar markets.
- RDDT is the larger of the two at $31.25B, about 57.0x CERS ($548.1M).
- Over the past year, CERS is up 104.5% and RDDT is down 26.1% - CERS leads by 130.6 points.
- RDDT has been more active in the news (13 items in the past 4 weeks vs 1 for CERS).
- RDDT has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- Reddit Inc.
- Price
- $2.72+0.93%
- $162.44+6.41%
- Market cap
- $548.1M
- $31.25B
- 1M return
- -11.11%
- -9.40%
- 1Y return
- +104.51%
- -26.08%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- 2024
- News (4w)
- 1
- 13
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Latest CERS
- Chief Legal Officer Jensen Chrystal sold $89,529 worth of shares (30,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 936,657 units (SEC Form 4)
- SEC Form S-8 filed by Cerus Corporation
- SEC Form 10-Q filed by Cerus Corporation
- Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cerus Corporation Announces Second Quarter 2026 Financial Results
- Chief Executive Officer Jayaraman Vivek K sold $52,665 worth of shares (16,666 units at $3.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.74% to 2,232,211 units (SEC Form 4)
- Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Financial Officer Green Kevin Dennis sold $99,105 worth of shares (33,676 units at $2.94) as part of a pre-agreed trading plan and gave a grant of 63,600 shares, decreasing direct ownership by 8% to 1,062,188 units (SEC Form 4) to cover withholding tax
- Chief Operating Officer Jayaraman Vivek K was granted 554,529 shares, gave a grant of 80,000 shares and sold $124,658 worth of shares (42,359 units at $2.94) as part of a pre-agreed trading plan, increasing direct ownership by 24% to 2,248,877 units (SEC Form 4) to satisfy withholding obligation
Latest RDDT
- CEO & President Huffman Steve Ladd converted options into 2,954 shares and covered exercise/tax liability with 40,336 shares (SEC Form 4) to cover withholding tax
- Chief Legal Officer Lee Benjamin Seong covered exercise/tax liability with 3,887 shares, decreasing direct ownership by 5% to 71,536 units (SEC Form 4) to satisfy tax liability
- Chief Accounting Officer Reynolds Michelle Marie covered exercise/tax liability with 1,265 shares, decreasing direct ownership by 8% to 13,795 units (SEC Form 4) to satisfy tax liability
- Chief Operating Officer Wong Jennifer L. covered exercise/tax liability with 38,113 shares, decreasing direct ownership by 4% to 1,012,226 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Vollero Andrew covered exercise/tax liability with 10,319 shares, decreasing direct ownership by 4% to 233,889 units (SEC Form 4) (tax withholding)
- CEO & President Huffman Steve Ladd exercised 18,000 shares at a strike of $25.29 and sold $3,206,893 worth of shares (18,000 units at $178.16) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Wong Jennifer L. exercised 75,000 shares at a strike of $9.34 and sold $13,391,000 worth of shares (75,000 units at $178.55) as part of a pre-agreed trading plan (SEC Form 4)
- Uniphore Launches Marketing AI to Usher in New Era: NYSE Content Update
- SEC Form 144 filed by Reddit Inc.
- Reddit Will Be Added to the S&P 500